TP53 and acquired polycythemia vera: Thus, 17% of HU-resistant patients corresponded to the TP53 disruption/aneuploidy category, while up to 40% were classified within the group with spliceosome/chromatin gene mutations, percentages clearly higher than the ones observed in non-resistant HU-treated controls and general PV patients [6].